8-K: ADC Therapeutics Reports Positive Q4 and Full Year 2024 Results, Highlights ZYNLONTA Progress

ADC Therapeutics announced its fourth quarter and full year 2024 financial results, showcasing progress with ZYNLONTA and providing operational updates.

Summary

• ADC Therapeutics reported financial results for Q4 and full year 2024, along with operational updates.
• ZYNLONTA achieved commercial brand profitability in 2024, generating $16.4 million in net product revenues for Q4 and $69.3 million for the full year.
• The company completed enrollment in the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL, with a data update anticipated in late 2025.
• Initial data from the LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab demonstrated a 94% best ORR and 72% CR rate, with a data update expected in the second quarter of 2025.
• R&D expense decreased to $27.1 million for Q4 and $109.6 million for the full year, due to productivity initiatives and focused investment.
• S&M expense decreased to $11.3 million for Q4 and $44.0 million for the full year, primarily due to lower marketing and advertising costs.
• G&A expense decreased to $9.6 million for Q4 and $41.9 million for the full year, related to lower professional fees and share-based compensation expense.
• Net loss for Q4 was $30.7 million, and for the full year, it was $157.8 million, primarily attributable to lower income tax expense and lower operating expenses.
• As of December 31, 2024, cash and cash equivalents were $250.9 million, providing runway expected to fund operations into the second half of 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the achievement of commercial profitability for ZYNLONTA, encouraging clinical trial data, and a strong cash position. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• ZYNLONTA achieved commercial brand profitability.
• Encouraging initial data from the LOTIS-7 trial.
• Completed enrollment in the LOTIS-5 trial.
• Reduced R&D, S&M, and G&A expenses.
• Decreased net loss compared to the previous year.
• Strong cash position to fund operations into the second half of 2026.

Negatives

• Quarter-over-quarter decrease in ZYNLONTA sales volume.
• Net loss of $157.8 million for the full year 2024, although improved from the previous year.

Risks

• The company's ability to grow ZYNLONTA revenue in the United States and to expand into combinations, earlier lines of therapy and new indications in the future.
• The ability of partners to commercialize ZYNLONTA in foreign markets and obtain regulatory approval.
• The timing, enrollment and results of research and development projects or clinical trials.
• The timing and outcome of regulatory submissions for products or product candidates.
• The company's indebtedness and the restrictions imposed on activities by such indebtedness.
• The ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness.
• The company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities.

Future Outlook

The company expects to provide updated data from the LOTIS-5 trial before the end of 2025 and believes it is well-positioned for success as it progresses toward additional pivotal milestones in 2025. The company expects its cash runway to fund operations into the second half of 2026.

Management Comments

• Ameet Mallik, Chief Executive Officer of ADC Therapeutics, stated that the company achieved several key milestones in 2024, including advancing expansion trials with ZYNLONTA, progressing the early research solid tumor program, and reducing operational spend while strengthening the balance sheet.
• He also mentioned the full enrollment of the LOTIS-5 DLBCL study and encouraging initial data from the LOTIS-7 DLBCL study.

Industry Context

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The company's focus on ADCs positions it within a rapidly evolving and competitive landscape of targeted cancer therapies. The progress of ZYNLONTA and the development of new ADCs targeting solid tumors are key to maintaining a competitive edge.

Comparison to Industry Standards

• ZYNLONTA's performance can be compared to other approved ADCs for hematologic malignancies, such as Adcetris (brentuximab vedotin) by Seagen and Polivy (polatuzumab vedotin) by Roche.
• The 94% ORR and 72% CR rate in the LOTIS-7 trial are promising and could position ZYNLONTA favorably against other combination therapies for r/r DLBCL.
• Companies like Immunogen, Mersana Therapeutics, and Daiichi Sankyo are also key players in the ADC space, with various clinical programs and approved products.
• The cash runway into the second half of 2026 provides ADC Therapeutics with financial stability comparable to other biotech companies of similar size and stage.

Stakeholder Impact

• Shareholders: Positive impact due to progress with ZYNLONTA and improved financial outlook.
• Employees: Positive impact due to company's continued operations and development programs.
• Patients: Potential positive impact due to the development of new cancer therapies.
• Creditors: Positive impact due to the company's strong cash position and ability to service debt.

Next Steps

• Complete enrollment of 40 patients in the dose expansion of LOTIS-7 in the second quarter of 2025.
• Share data on a subset of patients from LOTIS-7 in the second quarter of 2025.
• Provide a fuller, more mature data update from LOTIS-7 during the second half of 2025.
• Provide updated data from the LOTIS-5 trial before the end of 2025.
• Present abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025 in April.
• Engage regulatory agencies and evaluate compendia strategies based on investigator-initiated trial data.

Key Dates

Keywords

ZYNLONTA, ADC Therapeutics, Antibody Drug Conjugates, DLBCL, LOTIS-5, LOTIS-7, Financial Results, Hematologic Malignancies